Bikash Jhawar
Asia-Pacific Guide 2025
Band 2 : Restructuring/Insolvency
Band 2
About
Provided by Bikash Jhawar
Practice Areas
Banking & Finance
Insolvency & Restructuring
Projects, Energy & Infrastructure
Career
Bikash’s Banking & Finance [B&F] practice focuses primarily on rendering legal advice, structuring, drafting, risk allocation and negotiation assistance to borrowers & lenders for all their B&F needs.
Bikash possesses an expertise on infrastructure and PPP related laws & practices in India, foreign investment regulations & practices, and is sought out for advice on structuring investments into India.
Bikash is also active in advising Banks & Financial services providers and intermediaries, in some of their strategic activities. In this capacity he has interalia advised, Ratnakar Bank Limited in acquiring Royal Bank of Scotland’s commercial banking, credit cards & mortgage portfolio; Reliance Nippon Capital AMC in acquiring Goldman Sach’s mutual funds business in India; and is currently also advising in the establishment of a fin-tech accelerator and incubator program.
Bikash, as part of the Insolvency and Restructuring Practice, has acted on mandates on behalf of resolution professional, committee of creditors and prospective and successful resolution applicants in the restructuring and resolution of companies undergoing corporate insolvency resolution process.
He also assists Indian and foreign clients in legal risk management, and continuous legal review & support of their operations in India.
Chambers Review
Asia-Pacific
Bikash Jhawar is based in Mumbai and is active working on behalf of resolution applicants, resolution professionals and committees of creditors in insolvency processes. He handles matters across a range of sectors, including steel, manufacturing, power and infrastructure.
Articles, highlights and press releases
3 items provided by Saraf and Partners
Saraf and Partners elevates 5 Partners to Senior Partners
Saraf and Partners elevates 5 Partners to Senior Partners
Saraf and Partners acts for Viatris in its sale of biosimilars business to Biocon Biologics
Saraf and Partners acts for Viatris in its sale of biosimilars business to Biocon Biologics for US$ 3.335 billion
Saraf & Partners advised Viatris to sell its biosimilars business to Biocon Biologics for $3.335 b
Saraf & Partners advised Viatris to sell its biosimilars business to Biocon Biologics for $3.335 billion.
Saraf and Partners elevates 5 Partners to Senior Partners
Saraf and Partners elevates 5 Partners to Senior Partners
Saraf and Partners acts for Viatris in its sale of biosimilars business to Biocon Biologics
Saraf and Partners acts for Viatris in its sale of biosimilars business to Biocon Biologics for US$ 3.335 billion
Saraf & Partners advised Viatris to sell its biosimilars business to Biocon Biologics for $3.335 b
Saraf & Partners advised Viatris to sell its biosimilars business to Biocon Biologics for $3.335 billion.